Latest news with #Gabapentin
Yahoo
3 days ago
- Health
- Yahoo
Cause of death released for Redwood City inmate Kyle Harrison
(KRON) — A Redwood City street racer died in jail earlier this year shortly after he was sentenced for his role in causing a crash that left twin girls orphaned. On Monday, the San Mateo County Sheriff's Office released Kyle V. Harrison's cause of death. The county coroner's office determined that Harrison died on March 15 at Maple Street Correctional Facility in Redwood City 'due to toxic effects of three medications,' the sheriff's office wrote. The coroner concluded that the 25-year-old inmate's manner of death was an 'accident' and found Harrison died due to toxic effects of Methadone, Amitriptyline, and Gabapentin. Harrison previously pleaded no contest to engaging in a speed contest and felony vehicular manslaughter for the deaths of Grace Spiridon, and her husband, Gregory Ammen. The couple's 7-year-old daughters 'miraculously' survived the crash on El Camino Real, prosecutors said. In February, Harrison was sentenced to serve eight years in state prison. Court records show that Harrison was slated to be transported from the county jail to a state prison facility in May, but he died in jail before he was transferred. Investigators did not say why Harrison was taking Methadone, a medication typically used to treat opioid use disorder. Amitriptyline is an antidepressant medication. Gabapentin is an anticonvulsive medication that's also used to treat certain types of neural pain. The street race happened on Nov. 4, 2022 in Redwood City. Harrison raced his BMW against a teenager, Cesar Salto Morales, who was driving a Mercedes Benz on El Camino Real. Morales' Mercedes slammed into a Chevrolet Bolt with Spiridon, Ammen, and their two young daughters inside. The parents were killed on impact, while their daughters survived in the backseat. The family was less than 10 minutes away from their San Carlos home. Prosecutors said Harrison fled the scene, and a witness recorded his BMW's license plate number with her cellphone as he was driving away. Police found and arrested Harrison weeks later. After his in-custody death, the San Mateo County District Attorney's Office and San Mateo County Coroner's Office conducted independent investigations into Harrison's cause and manner of death. The DA's investigation is still underway. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hamilton Spectator
26-05-2025
- Hamilton Spectator
Fort Providence man pleads guilty to crack cocaine offence in Deline
A Fort Providence man was sentenced to 30 months, minus time served, and barred from owning a firearm for a decade after pleading guilty to possession of crack cocaine in Deline. In territorial court on May 16, John Minoza, 37, of Fort Providence, pleaded guilty to one count of possession of a controlled substance for the purpose of trafficking. He was also ordered to submit a DNA sample to the National DNA data bank. Court heard that Minoza was found in Deline on March 26, 2024, in breach of a court order to remain in Yellowknife following a police investigation into two other individuals who were attempting to bring an 'excess quantity of alcohol' into the community. Police intercepted the alcohol as it came off the flight and learned Minoza was in the community. When police located him, they also found 113 grams of crack cocaine, and 13 grams of a substance suspected to be Gabapentin — a prescription drug used to treat conditions like epilepsy, seizures and nerve pain. Deline RCMP said they were pleased with the outcome of the trial. 'This conviction is another example of the efforts made by the Deline RCMP to put an end to drug trafficking in the community,' said NT RCMP media relations officer Julie Plourde. 'The Northwest Territories RCMP is committed to target enforcement responses to reduce illegal drugs and alcohol in our communities. 'Anyone who has information about drug trafficking or bootlegging is asked to contact the Deline RCMP at 867-589-1111 or Crime Stoppers at . In the event of an emergency call, 911.'
Yahoo
20-05-2025
- Health
- Yahoo
An experimental painkiller could be the key to solving the opioid epidemic
An experimental drug developed by researchers at Duke University could be a key component in solving the nation's opioid epidemic. Known as 'SBI-810,' the drug avoids the 'high' that is tied to addiction to the pain-relieving drugs. The need for such a breakthrough is great, even as U.S. overdose deaths decline. Recent data showed they fell by 30,000 last year, but more than 80,000 people still died from the drugs. Drug overdose deaths have been increasing in the U.S. since the 1990s, mostly due to the use of opioids. 'What makes this compound exciting is that it is both analgesic and non-opioid,' Dr. Ru-Rong Ji, an anesthesiology and neurobiology researcher who directs the Duke Anesthesiology Center for Translational Pain Medicine, said in a statement. Well-known drugs like Advil and Tylenol are analgesic drugs, which are also known as painkillers. Ji was the senior author of the related Department of Defense- and National Institutes of Health-funded research, which was published on Monday in the journal Cell. Duke said the drug has undergone trials in mice, working well on its own. When used in combination with opioids, it made them more effective at lower doses, the authors said. Opioids increase levels of dopamine in the brain, which is often referred to as the 'happy hormone.' In turn, that dopamine and opioids work together to generate the high. But, over time, the body needs higher doses to feel the same effect. Like opioids, SBI-810 works on the nervous system to relieve pain. The experimental compound is designed to target a receptor – the brain receptor neurotensin receptor 1 – found on the spinal cord and nerve cells that function to transmit information to the central nervous system. The difference between opioids and SBI-810 is that Duke's drug takes a more focused approach than opioids. Instead of flooding multiple cellular pathways at the same time, the researcher noted, it activates only one specific pain-relief pathway that avoids that euphoric high. Furthermore, the researchers say it can prevent the common side effects that often force patients to need stronger and more frequent doses of opioids, including constipation and tolerance. It also outperformed the nerve pain drug gabapentin, and didn't cause sedation or memory problems often reported with that drug. Gabapentin is the seventh most commonly prescribed medication nationally. The authors have compared SBI-810 to oliceridine, a newer type of opioid used in hospitals. However, they found that SBI-810 worked better in some situations. It also effectively relieved pain from surgical incisions, bone fractures, and nerve injuries better than some existing painkillers, reducing signs of discomfort on a mouse's face. They hope to do human trials soon and have locked in multiple patients. Although the drug is still in early development, the authors said it could be a safer option for treating both short-term and chronic pain for those recovering from surgery or living with diabetic nerve pain. More than a third of Americans are living with chronic pain. 'The receptor is expressed on sensory neurons and the brain and spinal cord,' Ji added. 'It's a promising target for treating acute and chronic pain.'
&w=3840&q=100)
Business Standard
15-05-2025
- Business
- Business Standard
Here's why Marksans Pharma share price increased over 2% in trade on May 15
Marksans Pharma share price: Pharmaceutical company Marksans Pharma shares rose up to 2.18 per cent to hit an intraday high of ₹243.40 per share on Thursday, May 15, 2025. However, at 11:20 PM, Marksans Pharma shares pared gains and were trading merely 0.08 per cent higher at ₹238 per share. In comparison, BSE Sensex was trading 0.10 per cent lower at 81,247.08 level. Why led to the up move in Marksans Pharma share price? The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency (UK MHRA). In an exchange filing, Marksans Pharma said, 'Marksans Pharma hereby announces that its wholly owned subsidiary Relonchem Limited has received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.' Gabapentin is commonly used to treat epilepsy and nerve pain. In epilepsy, it's believed to work by calming abnormal electrical activity in the brain that leads to seizures. It's also effective for managing nerve pain, which may result from conditions such as diabetes, shingles, or physical injuries. Marksans Pharma results Marksans Pharma will release its March quarter of financial year 2025 (Q4FY25) results on May 19. The board will also consider recommending a dividend on the equity shares for FY25. In Q3FY25, Marksans Pharma's operating revenue stood at ₹681.8 crore, up 16.3 per cent year-on-year (Y-o-Y), driven growth across key markets, led by US region The gross profit stood at ₹383.5 crore, up 22.4 per cent Y-o-Y, with a gross margin expansion of 279 basis points (bps) Y-o-Y to 56.2 per cent. The growth was attributed to softening of raw material prices and a better product mix, the company said in a statement. About Marksans Pharma Marksans Pharma, based in Mumbai, specialises in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company operates manufacturing facilities in India, the USA, and the UK, all of which are approved by regulatory agencies, including the USFDA, UKMHRA, and Australian TGA. Marksans Pharma offers a diverse product portfolio across key therapeutic areas, such as cardiovascular (CVS), central nervous system (CNS), anti-diabetic, pain management, gastroenterology, and anti-allergies. These products are marketed worldwide.
Business Upturn
15-05-2025
- Business
- Business Upturn
Marksans Pharma's UK subsidiary Relonchem gets UKMHRA nod for Gabapentin oral solution
By News Desk Published on May 15, 2025, 09:26 IST Marksans Pharma Limited announced on May 15 that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) for Gabapentin 50 mg/ml oral solution. The regulatory approval marks a significant addition to the company's neurology-focused portfolio in the UK market. Gabapentin is commonly prescribed for the treatment of nerve pain and epilepsy. Marksans Pharma, headquartered in Mumbai, is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. Its facilities in India, the US, and the UK are approved by major global regulatory bodies including the USFDA, UKMHRA, and TGA Australia. The company's portfolio spans key therapeutic areas including cardiovascular, central nervous system (CNS), anti-diabetics, pain management, gastroenterology, and anti-allergy segments. Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making any investment decisions. News desk at
